Article
Biochemical Research Methods
Hina Khalid, Usman Ali Ashfaq
Summary: This study utilized a computational approach to screen phytochemicals with potential NS5B polymerase inhibition against Hepatitis C Virus. The top-ranked compounds showed a promising binding affinity and favorable safety profile, indicating their potential as antiviral compounds against HCV.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
(2022)
Article
Cell Biology
Kelsey A. Pilewski, Steven Wall, Simone I. Richardson, Nelia P. Manamela, Kaitlyn Clark, Tandile Hermanus, Elad Binshtein, Rohit Venkat, Giuseppe A. Sautto, Kevin J. Kramer, Andrea R. Shiakolas, Ian Setliff, Jordan Salas, Rutendo E. Mapengo, Naveen Suryadevara, John R. Brannon, Connor J. Beebout, Rob Parks, Nagarajan Raju, Nicole Frumento, Lauren M. Walker, Emilee Friedman Fechter, Juliana S. Qin, Amyn A. Murji, Katarzyna Janowska, Bhishem Thakur, Jared Lindenberger, Aaron J. May, Xiao Huang, Salam Sammour, Priyamvada Acharya, Robert H. Carnahan, Ted M. Ross, Barton F. Haynes, Maria Hadjifrangiskou, James E. Crowe Jr, Justin R. Bailey, Spyros Kalams, Lynn Morris, Ivelin S. Georgiev
Summary: In a study of a chronically HIV-1/HCV co-infected individual, researchers identified five cross-reactive antibodies that show exceptional neutralization breadth and effector functions against both HIV-1 and HCV. One antibody also cross-reacts with influenza and coronaviruses, including SARS-CoV-2. The development of these antibodies is closely related to somatic hypermutation, providing potential directions for therapeutic and vaccine development against current and emerging infectious diseases. Chronic co-infection represents a complex immunological challenge that can provide insights into the fundamental rules of antibody-antigen specificity.
Article
Gastroenterology & Hepatology
Andre Goemer, Mara Kloehn, Michelle Jagst, Maximilian K. Nocke, Sven Pischke, Thomas Horvatits, Julian Schulze zur Wiesch, Tobias Mueller, Svenja Hardtke, Markus Cornberg, Heiner Wedemeyer, Patrick Behrendt, Eike Steinmann, Daniel Todt
Summary: Chronic HEV infections are a significant issue in immunocompromised patients due to the absence of specifically approved antiviral drugs. A 24-week trial evaluated the efficacy of the nucleotide analog sofosbuvir in treating chronically HEV-infected patients, revealing the emergence of variants with lower sensitivity to the drug.
Article
Pharmacology & Pharmacy
Saima Mushtaq, Asraf Hussain Hashmi, Amjad Khan, Syed Muhammad Asad Raza Kazmi, Sobia Manzoor
Summary: Treatment-failing patients with hepatitis C virus often harbor NS5A resistance-associated substitutions (RASs), with A3OK, A62S/T and Y93H being the most frequent ones. Direct resistance testing is recommended for optimizing re-treatment strategies in these patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Toi Kobayashi, Takumi Yasuno, Kyoko Takahashi, Shigeo Nakamura, Tadahiko Mashino, Tomoyuki Ohe
Summary: In this study, four novel fullerene derivatives were synthesized, with some showing inhibitory effects on HIV-1 reverse transcriptase, HIV-1 protease, and HCV NS5B polymerase. Higher cellular uptake was observed for pyridinium/ethyl ester-type derivatives, indicating their potential as lead compounds for multitargeting drugs to treat HIV/HCV coinfection.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2021)
Article
Biochemistry & Molecular Biology
Mario Cano-Munoz, Samuel Jurado, Bertrand Morel, Francisco Conejero-Lara
Summary: The study highlights the crucial role of the HP in 6HB formation during HIV-1 infection. By investigating the binding behavior of the fluorescent dye ANS to the HP, potential lead compounds for HIV-1 therapeutics targeting the HP were identified. The study also reveals the influence of CHR peptide binding and allosteric connections on the conformational flexibility of the HP, providing insights for the development of small-molecule HIV-1 inhibitors.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)
Review
Gastroenterology & Hepatology
Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Yue Li, Yingying Zhao, Ben Li, Wei Li, Min Quan, Ying Duan, Hong Zhao, Danying Cheng, Xiaomei Wang, Weini Ou, Huichun Xing
Summary: This study analyzed the effectiveness of different drug regimens in treating HCV GT3-infected patients, including SOF + DCV +/- RBV, SOF + VEL +/- RBV, SOF + VEL + VOX, and GLE + PIB. Overall, these regimens showed high SVR rates in real-world studies, with GLE + PIB regimen having the highest SVR rate.
ANNALS OF HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Erwan Vo-Quang, Alexandre Soulier, Melissa Ndebi, Christophe Rodriguez, Stephane Chevaliez, Vincent Leroy, Slim Fourati, Jean-Michel Pawlotsky, EPIRES-C ANRS MIE Study Group
Summary: This study aimed to evaluate the proportion of non-1a/1b genotype 1 subtypes in HCV-infected patients who failed to achieve sustained virological response after first-line direct-acting antiviral treatment. It was found that patients infected with unusual HCV genotype 1 subtypes were overrepresented among treatment failures, with a majority of them being born in sub-Saharan Africa. These non-1a/1b genotype 1 subtypes naturally carry polymorphisms conferring reduced susceptibility to currently used drugs, particularly NS5A inhibitors. Retreatment with sofosbuvir plus an NS3 protease and an NS5A inhibitor is generally effective.
Article
Surgery
Cathy Logan, Ily Yumul, Javier Cepeda, Victor Pretorius, Eric Adler, Saima Aslam, Natasha K. Martin
Summary: Accepting hepatitis C virus (HCV)-viremic hearts for transplantation into HCV-negative recipients is cost-effective and improves clinical outcomes, with a willingness to accept any heart resulting in a gain in life-years and quality-adjusted life-years at a relatively low incremental cost-effectiveness ratio.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Gastroenterology & Hepatology
Rafael A. Leiva, Bente M. Bergersen, Ane-Kristine Finbraten, Per Kristian Sandvei, Oystein Simonsen, Carola M. Rosseland, Karin Hagen, Lital Young, R. Scott Roberts, Yngve Mikkelsen, Ravinder Singh, Martin Lagging, Olav Dalgard
Summary: This study evaluated the real-world effectiveness of 12 weeks of elbasvir/grazoprevir treatment without ribavirin and regardless of the baseline viral load and resistance associated substitutions (RAS) testing for hepatitis C virus genotype 1a infection. The results showed high sustained virologic response rates among patients, indicating the efficacy of the treatment regardless of baseline viral load and RAS testing.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Doaa Mohamed Abdelnajid, Ahmed Y. Elmowafy, Lionel Rostaing, Marwa T. Elrakaiby
Summary: This study aimed to evaluate the role of IL-28B gene polymorphism and IL-12 levels as predictors for the response to SOF/RBV treatment in hepatitis C virus patients. The results showed that IL-28B gene polymorphism and IL-12 levels play important roles in predicting DAAs resistance.
Article
Medicine, General & Internal
Ching-Chu Lo, Chung-Feng Huang, Pin -Nan Cheng, Kuo-Chih Tseng, Chi-Yi Chen, Hsing-Tao Kuo, Yi-Hsiang Huang, Chi-Ming Tai, Cheng-Yuan Peng, Ming-Jong Bair, Chien-Hung Chen, Ming-Lun Yeh, Chih-Lang Lin, Chun-Yen Lin, Pei-Lun Lee, Lee-Won Chong, Chao-Hung Hung, Te Sheng Chang, Jee-Fu Huang, Chi-Chieh Yang, Jui-Ting Hu, Chih-Wen Lin, Chun-Ting Chen, Chia-Chi Wang, Wei-Wen Su, Tsai-Yuan Hsieh, Chih-Lin Lin, Wei-Lun Tsai, Tzong-Hsi Lee, Guei-Ying Chen, Szu-Jen Wang, Chun-Chao Chang, Lein-Ray Mo, Sheng-Shun Yang, Wen-Chih Wu, Chia-Sheng Huang, Chou-Kwok Hsiung, Chien-Neng Kao, Pei-Chien Tsai, Chen-Hua Liu, Mei-Hsuan Lee, Chun-Jen Liu, Chia-Yen Dai, Wan-Long Chuang, Han-Chieh Lin, Jia-Horng Kao, Ming-Lung Yu
Summary: This study evaluated the antiviral effectiveness of ledipasvir/sofosbuvir in chronic hepatitis C patients in Taiwan and found that the treatment achieved high cure rates across different patient populations.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2022)
Article
Biochemistry & Molecular Biology
Hamed Esmaeil Lashgarian, Ali Valibeik, Abdolrazagh Marzban, Maryam Karkhane, Kiana Shahzamani
Summary: The study found no relationship between NS5A mutations and treatment response, indicating that sequencing of NS5A may not be a suitable tool for predicting treatment outcomes. No significant difference was observed in mutations before and after treatment among responders and non-responders.
REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2021)
Article
Gastroenterology & Hepatology
Hsien-Hong Lin, Shih-Jer Hsu, Sheng-Nan Lu, Wan-Long Chuang, Chao-Wei Hsu, Rong-Nan Chien, Sien-Sing Yang, Wei-Wen Su, Jaw-Ching Wu, Tzong-Hsi Lee, Cheng-Yuan Peng, Kuan-Chiao Tseng, Albert Qin, Yi-Wen Huang, Pei-Jer Chen
Summary: This study compared the pharmacokinetics, safety, and preliminary efficacy of ropeginterferon alfa-2b with PEG-IFN-alpha 2a in patients with chronic hepatitis C virus genotype 1 infection. Results showed that ropeginterferon alfa-2b had a longer effective half-life and superior safety profile compared to PEG-IFN-alpha 2a, indicating its potential for further study in a larger population of viral hepatitis patients.